Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?

ERJ Open Res. 2016 May 26;2(2):00055-2016. doi: 10.1183/23120541.00055-2016. eCollection 2016 Apr.

¹ Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; Lung Clinic Immenhausen, Immenhausen, Germany.
² Dept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
³ University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases, Groningen, The Netherlands.
⁴ Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; Dept of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.

Abstract

SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiovascular risk http://ow.ly/p6Is300ffoc.